Core Viewpoint - The company, Shuoshi Biological (688399.SH), announced voluntary salary reductions for several executives, including a 50% cut for the honorary chairman and the chairman/general manager, as a response to ongoing industry challenges and to demonstrate solidarity during tough times [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman/general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua (director and deputy general manager), Hu Yuanyuan (director, deputy general manager, and board secretary), and Zhou Guohui (deputy general manager), will see a 40% salary reduction [2][3]. - The financial director, Meng Yuanyuan, and employee supervisors, Jia Zhaoqiang and Gu Lina, will have their salaries reduced by 10% and 5%, respectively [2][3]. Financial Performance - The company reported a revenue of 176 million yuan in the first half of 2025, a decrease of 1.05% year-on-year, with a net profit of 3.99 million yuan, down 86.35% [6]. - Shuoshi Biological has experienced consecutive years of losses, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively, and corresponding net profits of -374 million yuan and -2 million yuan [6]. - Despite the decline in performance, the company plans to distribute a cash dividend of 2.85 billion yuan to shareholders, reflecting a commitment to return value to investors [6]. Company Overview - Shuoshi Biological focuses on the research, production, and sales of in vitro diagnostic reagents and related testing instruments, expanding into in vitro testing services to achieve an integrated business model [6].

Core Viewpoint - The company, Shuoshi Biotechnology, announced voluntary salary reductions for its board members and senior management, reflecting their commitment to navigate industry challenges and enhance long-term development [2] Group 1: Salary Adjustments - The salary reductions range from 5% to 50%, effective from August 15, 2025, with the chairman and general manager's salary reduced by 50% [2] - Specific reductions include a 40% cut for two vice presidents, a 10% cut for the financial director, and a 5% cut for one employee supervisor [2] Group 2: Financial Performance - In 2024, the company reported a revenue of 350 million yuan, a year-on-year decline of 13.29%, and a net profit loss of 2 million yuan, although this represented a significant reduction in losses compared to the previous year [3] - The company experienced a sharp decline in net profit in 2023, with a loss of 374 million yuan, a 120.45% decrease year-on-year [3][5] Group 3: R&D and Market Strategy - The company increased its R&D investment to 28.86% of revenue in 2024, focusing on product line optimization and new solutions in infectious disease prevention and cancer diagnostics [6] - Despite a 37.89% increase in overseas revenue, the overall contribution of international sales remains limited, failing to offset the decline in the domestic market [6]

Core Viewpoint - The company, Shuoshi Biotechnology, announced voluntary salary reductions for several board members and senior management to support operational cost optimization and enhance management efficiency in response to challenging global economic conditions [1][3]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua and Hu Yuanyuan, will see a 40% reduction, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [2][3]. Company Performance - Shuoshi Biotechnology reported a significant decline in net profit, with a loss of 374 million yuan in 2023, a 120.45% decrease year-on-year [5][6]. - The company’s revenue for the first half of 2025 was 176 million yuan, a decrease of 1.05% compared to the previous year, with a net profit of 3.99 million yuan, down 86.35% year-on-year [5][6]. Future Strategies - In addition to salary adjustments, the company plans to continue cost-cutting measures and enhance market expansion efforts to improve operational efficiency and competitiveness [4][5].

Core Viewpoint - The management team of Shuoshi Biotechnology (SH688399) voluntarily decided to reduce their salaries to support the company's operational cost optimization and enhance management efficiency amid challenging global economic conditions and industry environment [1][3]. Salary Reduction Details - The salary reductions include: - Honorary Chairman Fang Yongsheng: 50% reduction starting from August 15, 2025 - Chairman and General Manager Wang Guoqiang: 50% reduction starting from August 15, 2025 - Director and Deputy General Manager Liu Zhonghua: 40% reduction starting from August 15, 2025 - Director, Deputy General Manager, and Board Secretary Hu Yuanyuan: 40% reduction starting from August 15, 2025 - Deputy General Manager Zhou Guohui: 40% reduction starting from August 15, 2025 - Chief Financial Officer Meng Yuanyuan: 10% reduction starting from August 15, 2025 - Employee Supervisor Jia Zhaoqiang: 10% reduction starting from August 15, 2025 - Employee Supervisor Gu Lina: 5% reduction starting from August 15, 2025 [2]. Company Performance and Financials - In 2023, Shuoshi Biotechnology reported a significant loss with a net profit of -374 million yuan, a 120.45% decline year-on-year [6]. - For 2024, the company is expected to continue reporting losses, with a projected revenue decline of 13.29% [6]. - The company's revenue for the first half of 2025 was 176 million yuan, a 1.05% decrease year-on-year, with a net profit of 3.99 million yuan, down 86.35% from the previous year [6]. - The decline in profitability is attributed to price pressures from national procurement in the in vitro diagnostics industry and changes in tax rates affecting gross margins [6]. Cost Management Efforts - The company is actively pursuing cost reduction and efficiency improvement measures, alongside salary adjustments, to enhance operational efficiency and market competitiveness [3]. - Sales expenses, management expenses, and R&D expenses have all decreased during the reporting period, with sales expenses at 64.25 million yuan (down 1.94%), management expenses at 31.68 million yuan (down 21.02%), and R&D expenses at 40.64 million yuan (down 13.11%) [6]. R&D Investment - The proportion of R&D investment relative to revenue was 23.15%, a decrease of 3.21 percentage points year-on-year [7].

Core Viewpoint - The management team of Shuoshi Biotechnology (SH688399) voluntarily decided to reduce their salaries to support the company's operational cost optimization and enhance management efficiency in response to the challenging global economic environment and industry conditions [1][3]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2]. - Other executives, including Liu Zhonghua and Hu Tongyuan, will see a 40% salary reduction, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [2]. Company Performance and Financials - In 2023, Shuoshi Biotechnology reported a significant loss, with a net profit of -374 million yuan, a decrease of 120.45% year-on-year [6]. - The company's revenue for the first half of 2025 was 176 million yuan, down 1.05% year-on-year, with a net profit of 3.99 million yuan, reflecting an 86.35% decline compared to the previous year [6]. - The decline in profitability is attributed to price pressures from national procurement in the in vitro diagnostics industry and changes in tax rates affecting gross margins [6]. Cost Management and Operational Efficiency - The company is committed to ongoing cost reduction and efficiency improvement measures, alongside expanding market reach to enhance operational efficiency and competitiveness [3]. - Sales, management, and R&D expenses have all decreased, with sales expenses at 64.25 million yuan (down 1.94%), management expenses at 31.68 million yuan (down 21.02%), and R&D expenses at 40.64 million yuan (down 13.11%) [6]. R&D Investment - R&D investment accounted for 23.15% of the company's revenue, which is a decrease of 3.21 percentage points year-on-year [7].

Core Viewpoint - The company, Shuoshi Biotechnology, announced voluntary salary reductions by its board members and senior management to support operational cost optimization and enhance competitiveness amid challenging global economic conditions [2][4]. Group 1: Salary Reductions - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [3]. - Other executives, including Liu Zhonghua and Hu Yuanyuan, will see a 40% reduction in their annual salaries, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [3]. Group 2: Company Performance - In the first half of 2025, the company reported revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million yuan, down 86.35% year-on-year [4]. Group 3: Strategic Initiatives - The company emphasized that the salary adjustments reflect management's recognition of the company's intrinsic value and confidence in future growth prospects [4]. - In addition to salary cuts, the company plans to implement cost-reduction measures and enhance market expansion efforts to improve operational efficiency and competitiveness [4].

Core Viewpoint - The management team of Shuoshi Biotechnology has voluntarily agreed to salary reductions to support the company's operational optimization and enhance management efficiency amid ongoing financial struggles [2][3]. Salary Reduction Details - Eight senior executives, including Honorary Chairman Fang Yongsheng and Chairman & General Manager Wang Guoqiang, will see salary cuts ranging from 5% to 50%, effective from August 15, 2025 [3][4]. - The most significant reduction is a 50% cut for both Fang Yongsheng and Wang Guoqiang, while other executives will experience reductions of 40% and 10% [4]. Financial Performance - Shuoshi Biotechnology has faced consecutive years of losses, with a reported net loss of 374 million yuan in 2023, a decline of 120.45% year-on-year [7]. - For the first half of 2025, the company reported a revenue of 176 million yuan, a decrease of 1.05% compared to the previous year, and a net profit of 3.99 million yuan, down 86.35% year-on-year [7][8]. Executive Compensation - Despite the financial difficulties, seven executives had annual salaries exceeding one million yuan in 2024, with Fang Yongsheng earning 2.0643 million yuan and Wang Guoqiang earning 2.4399 million yuan [5][6]. - The company emphasizes that the salary adjustments reflect the management's commitment to the company's long-term development and recognition of its intrinsic value [4][5]. Market Position - As of August 28, the stock price of Shuoshi Biotechnology was 63.08 yuan per share, with a total market capitalization of 5.3 billion yuan [9].

北京商报讯(记者丁宁)8月27日晚间，硕世生物(688399)发布公告称，公司近日收到部分董事、监事及全 体高级管理人员主动出具的《关于自愿降薪的函》。当前，全球经济形势及行业环境面临诸多挑战，为 进一步支持公司优化运营成本、提升管理效率、增强持续竞争力，实现稳健发展战略目标，上述人员基 于对公司未来发展的坚定信心及共同担当，自愿提出调整薪酬。 具体来看，名誉董事长房永生，董事长、总经理王国强年薪下调50%；董事、副总经理刘中华，董事、 副总经理、董事会秘书胡园园，副总经理周国辉年薪下调40%；财务总监孟元元，职工监事贾兆强年薪 下调10%；职工监事顾丽娜年薪下调5%。 此外，硕世生物称，除进行薪酬调整外，公司还将持续推进降本增效举措、加大市场拓展力度，从多维 度提升公司的运营效率和市场竞争力。 硕世生物表示，本次降薪系公司董事、监事及高级管理人员在充分理解行业周期与市场环境的基础上， 主动与公司共度时艰、共谋长远发展的重要体现，充分展现了管理层对公司内在价值的高度认同及对未 来成长前景的强烈信心。公司对此表示高度赞赏和衷心感谢，并将持续优化经营，积极应对市场变化， 不断提升价值创造能力，切实维护全体股东利益 ...

Meeting Overview - The shareholder meeting of Jiangsu Shuoshi Biotechnology Co., Ltd. was held on August 27, 2025, at the company's conference room in Taizhou, Jiangsu [1] - A total of 111 ordinary shareholders attended the meeting, representing 37,537,572 voting rights, which accounts for 44.7559% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with a high level of agreement, including 99.9804% of votes in favor for one proposal and 99.8292% for another [1] - The voting results for the cash dividend proposal showed that the majority of shareholders supported the proposal, with detailed breakdowns provided for different shareholder categories [2] Legal Compliance - The lawyers present confirmed that the meeting's convening and voting procedures complied with relevant laws and the company's articles of association, ensuring the legality and validity of the meeting and its outcomes [3]

江苏硕世生物科技股份有限公司 除进行薪酬调整外，公司还将持续推进降本增效举措、加大市场拓展力度， 从多维度提升公司的运营效率和市场竞争力。公司董事会、监事会及管理层将坚 守初心，始终如一地恪尽职守、勤勉尽责，为公司及全体股东的长远利益不懈努 力。 关于公司部分董事、监事及全体高级管理人员自愿降 薪的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）近日收到部分董事、 监事及全体高级管理人员主动出具的《关于自愿降薪的函》。当前，全球经济形 势及行业环境面临诸多挑战，为进一步支持公司优化运营成本、提升管理效率、 增强持续竞争力，实现稳健发展战略目标，上述人员基于对公司未来发展的坚定 信心及共同担当，自愿提出调整薪酬。现将本次降薪有关事项公告如下： | 降薪对象 | 降薪幅度 | | | | | | 降薪期限 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名誉董事长房永生先 | | | | | | | | ...